Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Enzymes and Inhibitors
  4. Modifying Enzymes
  5. Tocris Bioscience™ CCG 1423

Tocris Bioscience™ CCG 1423

Catalog No. 523310
Change view
Click to view available options
Quantity:
10 mg
50 mg
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
52-331-0 10 mg
52-335-0 50 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
This item is not returnable. View return policy
Catalog No. 52-331-0 Supplier Tocris Bioscience™ Supplier No. 5233/10
This item is not returnable. View return policy

Description

Induces intermediate mesoderm differentiation from ESCs; Rho/SRF pathway inhibitor

CCG 1423 is a Rho/SRF pathway inhibitor; stimulates apoptosis of a melanoma cell line overexpressing RhoC (A375M2). Suppresses Rho-dependent invasion of PC-3 prostate cancer cells in vitro and inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells. When used in combination with Retinoic acid, LY 294002 and Pyridone 6, it induces intermediate mesoderm differentiation from ESCs.

Specifications

Purity >99%
Quantity 10 mg
Product Type CCG 1423
Molecular Weight (g/mol) 454.75
Inhibitors Rho GTPase Inhibitors

For Research Use Only

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.